Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Journal articles and book chapters

03-28-2018 | Cardiovascular disorders | Article

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death, and safety outcomes in type 2 diabetes: A systematic review

Rådholm K et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.03.027

03-27-2018 | Nephropathy | Review | Article

New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors

Dekkers CCJ, Gansevoort RT, Heerspink HJL. Curr Diab Rep 2018; 18: 27. doi: 10.1007/s11892-018-0992-6

03-25-2018 | SGLT2 inhibitors | Article

Sodium‐glucose co‐transporter‐2 inhibitors as add‐on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials

Yamada T et al. Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13260

03-23-2018 | Oral combination medications | Article

SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Li D et al. Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13294

03-23-2018 | SGLT2 inhibitors | Article

SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: A systematic review and meta‐analysis

Guo M et al. Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13295

02-27-2018 | SGLT2 inhibitors | Article

SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials

Puckrin R et al. Acta Diabetol 2018; Advance online publication. doi: 10.1007/s00592-018-1116-0

02-06-2018 | Healthcare costs | Article

Cost-effectiveness analysis of canagliflozin 300 mg versus dapagliflozin 10 mg added to metformin in patients with type 2 diabetes in the United States

Neslusan C et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0371-y

02-06-2018 | Post-transplant diabetes mellitus | Review | Article

Post-liver transplantation diabetes mellitus: A review of relevance and approach to treatment

Peláez-Jaramillo MJ et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0374-8

01-25-2018 | Heart failure | Review | Article

Effect of glucose-lowering therapies on heart failure

Nat Rev Cardiol 2018; Advance online publication. doi: 10.1038/nrcardio.2017.211

01-11-2018 | Cardiovascular outcomes | Review | Article

Direct cardiovascular impact of SGLT2 inhibitors: Mechanisms and effects

Kaplan A et al. Heart Fail Rev 2018; 23: 419–437. doi: 10.1007/s10741-017-9665-9

01-09-2018 | Pathophysiology | Review | Article

Sodium–glucose transporter as a novel therapeutic target in disease

Yamazaki Y et al. Eur J Pharmacol 2018; 822: 25–31. doi: 10.1016/j.ejphar.2018.01.003

01-08-2018 | Ertugliflozin | Article

Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: The VERTIS SITA randomized study

Miller S et al. Diabetes Ther 2018; 9: 253–268. doi: 10.1007/s13300-017-0358-0

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

01-04-2018 | Medication adherence | Article

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study

McGovern A et al. Diabetes Ther 2018; 9: 229–242. doi: 10.1007/s13300-017-0361-5

12-27-2017 | Ertugliflozin | Article

Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study

Hollander P et al. Diabetes Ther 2017; 9: 193–207. doi: 10.1007/s13300-017-0354-4

12-01-2017 | SGLT2 inhibitors | Article

Effectiveness of long-term treatment with SGLT2 inhibitors: Real-world evidence from a specialized diabetes center

Thewjitcharoen Y et al. Diabetol Metab Syndr 2017; 9: 96. doi: 10.1186/s13098-017-0297-y

11-20-2017 | Ertugliflozin | Article

Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study

Grunberger G et al. Diabetes Ther 2018; 9: 49–66. doi: 10.1007/s13300-017-0337-5

11-02-2017 | Heart failure | Review | Article

Treating disease mechanisms in patients with heart failure and diabetes mellitus

Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

10-23-2017 | Insulin | Review | Article

Insulin and its cardiovascular effects: What is the current evidence?

Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep 2017; 17: 120. doi: 10.1007/s11892-017-0955-3

10-23-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

Next Previous